Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (symbol: SENS) is a pioneering medical technology firm based in Germantown, Maryland. The company's primary focus is on developing and commercializing advanced glucose monitoring systems that significantly improve the lives of people managing diabetes. Utilizing cutting-edge fluorescence sensing technology, Senseonics has designed the Eversense Continuous Glucose Monitoring (CGM) System, recognized for being the first fully implantable CGM system. This system comprises a tiny sensor implanted under the skin, an external smart transmitter, and a user-friendly mobile application, allowing for real-time glucose monitoring without the need for a dedicated receiver.
The Eversense CGM System stands out for its accuracy and stability throughout its extended sensor life, offering continuous glucose monitoring for up to 180 days. This long-term solution provides an alternative to traditional short-term CGMs, catering to individuals who require a more stable and reliable glucose monitoring option.
Senseonics has established strong partnerships, including a notable collaboration with Ascensia Diabetes Care, which ensures that their innovative solutions reach a global audience. Their latest product, the Eversense E3 CGM System, is part of an extended assistance program known as the Eversense Payment Assistance and Simple Savings (PASS) Program. This program offers eligible individuals in the U.S. the opportunity to access the Eversense E3 systems at a significantly reduced out-of-pocket cost of $99 for each six-month period, thereby making continuous glucose monitoring more affordable.
Senseonics is committed to advancing diabetes management technology, as evidenced by their continued innovation and dedication to improving accessibility to their products. The company's forward-looking approach and strategic alliances position them as a key player in the medical technology landscape, specifically in the context of diabetes management.
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems for diabetes patients, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA.
The company will deliver a corporate overview and conduct one-on-one meetings during the conference on Tuesday, March 4, 2025, at 3:10 pm ET. Interested parties can access both live and recorded webcasts of the presentation through the 'Investor Relations' section of Senseonics' website at www.senseonics.com.
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has scheduled its fourth quarter and full year 2024 earnings release for March 3, 2025, after market close.
The company will host a conference call at 4:30 P.M. Eastern Time on the same day to discuss the financial results. Investors can access the call by dialing 1-800-445-7795 (US/Canada) or 1-785-424-1699 (International) using passcode SENSQ4. A concurrent webcast will be available on the company's website under the Investor Relations section and will be archived for future reference.
Senseonics Holdings (NYSE: SENS) has submitted a CE Mark registration for its Eversense 365 CGM system, the world's first one-year continuous glucose monitoring system. The device, already FDA-approved and launched in the US in October 2024, could soon be commercialized across EU member countries through Ascensia Diabetes Care.
The Eversense 365 system offers significant advantages over traditional short-term CGMs, including: year-long duration, removable smart transmitter, trusted alerts with exceptional accuracy, comfortable silicone-based adhesives, and weekly calibration requirements. Following CE Mark approval, the company plans distribution in Germany, Italy, Spain, Poland, Switzerland, and Sweden.
The system is cleared in the US as an integrated CGM (iCGM) system, compatible with insulin pumps for automated insulin delivery (AID) systems, with ongoing partnership discussions with pump manufacturers.
Senseonics Holdings (NYSE: SENS) announced preliminary Q4 2024 revenue of $8.3 million and full-year revenue of $22.5 million. The company reported significant growth following the FDA approval and launch of Eversense® 365, their implantable continuous glucose monitoring system.
Key achievements include a 56% increase in global patient base to 6,000, reaching over 1,000 U.S. prescribers in 2024. Post-launch indicators show doubled Direct to Consumer leads in Q4, record-high monthly patient shipments of 600 in December, and a 49% increase in patients switching from competitors. The company maintained approximately $74.9 million in cash and equivalents as of December 31, 2024.
Senseonics canceled its planned Special Meeting for a reverse stock split, citing recent share price appreciation. The company expects positive revenue growth in 2025, with detailed guidance to be provided with full fiscal year 2024 results.
Senseonics Holdings (NYSE: SENS) reported strong early performance indicators for its Eversense 365 launch, which began shipping in November. Key highlights include: doubled Direct-to-Consumer leads in October and November compared to pre-launch months, highest new patient shipments since Ascensia partnership began, 42% increase in prescribing providers, and 69% increase in prescriptions from top prescribers.
The company maintains its target of 50% annual growth in patient installed base for 2024 and reiterates global net revenue guidance of approximately $22 million. One-third of Eversense 365 prescribers are first-time users, and patient switches from competitive CGMs have increased 47% since launch. The company plans a reverse stock split in January 2025 to enhance appeal to institutional investors.
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its participation in two upcoming investor conferences in November. The company will present at the Stifel 2024 Healthcare Conference on November 19, delivering a corporate overview and holding one-on-one meetings, with a presentation scheduled for 9:10 am ET. Additionally, management will participate in the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 21, conducting one-on-one meetings. Both events will be accessible via webcast through the company's investor relations website.
Senseonics Holdings reported Q3 2024 financial results with total revenue of $4.3 million, down from $6.1 million in Q3 2023. The company announced FDA approval for Eversense 365, the world's first 365-day CGM system. Q3 net loss was $24.0 million ($0.04 per share). The company raised over $20 million from equity offerings and implemented restructuring targeting $10M cost reduction in 2025. Full-year 2024 global revenue guidance is approximately $22 million. Cash position stood at $74.8 million with $55.9 million in debt as of September 30, 2024.
Senseonics Holdings (NYSE American: SENS) has announced a $16 million registered direct offering of 45,714,286 common stock shares at $0.35 per share. The company will also issue unregistered warrants to purchase an additional 45,714,286 shares at $0.35 per share in a concurrent private placement. The warrants will be exercisable after six months and expire after five years, potentially generating an additional $16 million if fully exercised. The proceeds will be used for working capital, general corporate purposes, and potentially repaying borrowings on 5.25% Convertible Senior Notes due 2025. The offering is expected to close around October 28, 2024.
Senseonics Holdings (NYSE American: SENS), a medical technology company developing long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its upcoming third quarter 2024 financial results release. The results will be disclosed after market close on Thursday, November 7, 2024, followed by a conference call at 4:30 p.m. Eastern Time. Investors can access the webcast through the company's website or join via phone using the provided dial-in numbers.
Senseonics Holdings (NYSE American: SENS) announced a virtual KOL event on October 25, 2024, at 11:00am ET to discuss the Eversense® 365 Continuous Glucose Monitoring (CGM) system. This next-generation system, recently cleared by the FDA for people with Type 1 and Type 2 diabetes aged 18 and older, is the world's first one-year CGM system.
The event will feature Dr. David T. Ahn from Hoag Medical Group and Dr. Jeff Ciaramita from Mercy health system, along with company management. They will highlight Eversense 365 in clinical practice and provide an overview of Senseonics' commercial collaboration with Mercy. A live Q&A session will follow the presentations.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
What does Senseonics Holdings, Inc. specialize in?
What is the Eversense Continuous Glucose Monitoring (CGM) System?
How long can the Eversense CGM System monitor glucose levels?
What is the Eversense Payment Assistance and Simple Savings (PASS) Program?
How does Senseonics' CGM technology benefit people with diabetes?
Where is Senseonics Holdings, Inc. headquartered?
Who are Senseonics' key partners?
How can I learn more about the Eversense CGM System?
Is the Eversense CGM System available outside the United States?
What is the mission of Senseonics Holdings, Inc.?
